A Phase 2 interventional study of Artemisinin / Artesunate and placebo in Covid 19 Positive and Corona Virus Infection, sponsored by Princess Nourah Bint Abdulrahman University. Withdrawn at 1 site in Saudi Arabia. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2022-05-02.
Sponsored by Princess Nourah Bint Abdulrahman University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus.
At this time, there are no specific vaccines or treatments for COVID-19. However, there are many ongoing clinical trials evaluating potential treatments Drugs used to treat malaria infection has shown to be beneficial for many other diseases, including viral infections.
In this Clinical trial, Investigators will evaluate the effect of Artemisinin / Artesunate on morbidity of COVID-19 patients in decreasing the course of the disease and viral load in symptomatic stable positive swab COVID-19 patients. Investigators are hypothesizing that due to the antiviral properties of this drug it will help as a treatment for the COVID -19 patients. In improving their condition and clearing the virus load,
In this Clinical trial, Investigators will evaluate the effect of Artemisinin / Artesunate on morbidity of COVID-19 patients in decreasing the course of the disease and viral load in symptomatic stable positive swab COVID-19 patients. investigators are hypothesizing that due to the antiviral properties of this drug it will help as a treatment for the COVID -19 patients. In improving their condition and clearing the virus load, investigators are testing two groups the one that will take the drug and then compare them to a placebo group that will not take any drug for the treatment in a blinded fashion made by randomization done by our pharmacy team so investigators eliminate risk of bias. Our expectation is to find a total reduction of the hospital stay to 7 days instead of 14 days currently indicating the effectiveness of the medication in eradicating the virus.
1,112 studies on the registry are indexed under Coronavirus Infections; 51 are open to participants now.
Browse Coronavirus Infections studies →Princess Nourah Bint Abdulrahman University is the lead sponsor of 31 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who have sever disease- shortness of breath, sick patients or admitted in ICU
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
this group will receive the Artemisinin / Artesunate 100mg once daily for 5 days
Drug: Artemisinin / Artesunate
this group will receive a placebo of the same shape and picture of the study drug
Other: placebo
Drug pages: ArtemisininStudies of ArtemisininArtemisinin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ArtesunateStudies of ArtesunateArtesunate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
testing the drug capabilities in reducing the shedding and causing the testing for covid 19 to become negative
placebo or sham drug will be given to the second arm
length of stay in hospital
absence of the virus shedding evidenced by negative swabs
Time frame: within the first 6 days intervention
number of ICU admission
reduction of morbidity and mortality
Time frame: 14 days
resolution of symptoms
finding the time that the symptoms disappear
Time frame: 6 days - 10 day
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2022; primary completion for Sep 2022, 8 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Artemisinin · Artesunate
Princess Nourah Bint Abdulrahman University